Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab plus topical corticosteroids in adults with severe atopic dermatitis unsuitable for cyclosporine A
NL-OMON43809Phase 3Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dupilumab in atopic dermatitis (AD), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Proportion of patients achieving EASI 75 at week 16. Started Apr 2016; status: active, not recruiting.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON43809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43809.